Literature DB >> 6891841

A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma.

J H Verheijen, E Mullaart, G T Chang, C Kluft, G Wijngaards.   

Abstract

An indirect spectrophotometric assay for extrinsic plasminogen activator has been devised, which is based on the parabolic assay of Drapier et al. (5). The system contains activator, plasminogen, the synthetic plasmin substrate H-D-Val-Leu-Lys-pNA (S-2251, Kabi) and a mixture of soluble fibrinogen fragments prepared by treatment of fibrinogen with cyanogen bromide. The addition of these fibrinogen fragments considerably enhances the sensitivity and specificity of the method owing to specific stimulation of the plasminogen activation by extrinsic plasminogen activator. The assay conditions were optimized and the application for extrinsic plasminogen activator measurements in plasma euglobulin fractions is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6891841

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  66 in total

1.  Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.

Authors:  Andre L Samson; Simon T Nevin; David Croucher; Be'eri Niego; Philip B Daniel; Thomas W Weiss; Eliza Moreno; Denis Monard; Daniel A Lawrence; Robert L Medcalf
Journal:  J Neurochem       Date:  2008-09-15       Impact factor: 5.372

2.  Fractionation of heparin by chromatography on a tissue plasminogen activator-Sepharose column.

Authors:  P Andrade-Gordon; S Strickland
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

Authors:  C Kluft; H K Nieuwenhuis; D C Rijken; E Groeneveld; G Wijngaards; W van Berkel; G Dooijewaard; J J Sixma
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

4.  Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.

Authors:  D E Vaughan; P J Declerck; M De Mol; D Collen
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Different Effects of Lipopolysaccharide on Plasminogen Activator Inhibitor-1 Production in Aortic Media in Vivo and in Culture.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

6.  Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans.

Authors:  Tom van der Poll; Marcel Levi; Jerry A Nick; Edward Abraham
Journal:  Am J Respir Crit Care Med       Date:  2005-03-04       Impact factor: 21.405

7.  DMSO-induced changes in the procoagulant and fibrinolytic activity of B16 melanoma cells: influence on lung colony formation.

Authors:  B Casali; M G Lampugnani; M Riganti; A Niewiarowska; G Alessio; L Mussoni; N Semeraro; M B Donati
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

8.  Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.

Authors:  Marcel Schouten; Koenraad F van der Sluijs; Bruce Gerlitz; Brian W Grinnell; Joris J T H Roelofs; Marcel M Levi; Cornelis van 't Veer; Tom van der Poll
Journal:  Crit Care       Date:  2010-04-14       Impact factor: 9.097

9.  Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.

Authors:  Marcel Schouten; Cornelis van't Veer; Joris J T H Roelofs; Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

10.  Procoagulant and fibrinolytic activity in ventilator-associated pneumonia: impact of inadequate antimicrobial therapy.

Authors:  Ali A El-Solh; Mifue Okada; Celestino Pietrantoni; Alan Aquilina; Eileen Berbary
Journal:  Intensive Care Med       Date:  2004-07-23       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.